Advertisement

Effect of risk-reducing salpingo-oophorectomy on sex steroid hormone serum levels among postmenopausal women: an NRG Oncology/Gynecologic Oncology Group study

Published:February 22, 2022DOI:https://doi.org/10.1016/j.ajog.2022.02.022

      Background

      Risk-reducing salpingo-oophorectomy is an effective ovarian cancer risk reduction strategy. However, bilateral oophorectomy has also been associated with increased long-term nonneoplastic sequelae, effects suggested to be mediated through reductions in systemic sex steroid hormone levels. Currently, it is unclear whether the postmenopausal ovary contributes to the systemic hormonal milieu or whether postmenopausal ovarian volume or other factors, such as body mass index and age, affect systemic hormone levels.

      Objective

      We examined the impact of oophorectomy on sex steroid hormone levels in postmenopausal women. Furthermore, we explored how well ovarian volume measured by transvaginal ultrasound correlated with direct ovarian measures obtained during surgical pathology evaluation and investigated the association between hormone levels and ovarian volumes.

      Study Design

      Postmenopausal women who underwent risk-reducing salpingo-oophorectomy (180 cases) or ovarian cancer screening (38 controls) enrolled in an international, prospective study of risk-reducing salpingo-oophorectomy and risk of ovarian cancer algorithm–based screening among women at increased risk of ovarian cancer (Gynecologic Oncology Group-0199) were included in this analysis. Controls were frequency matched to the cases on age at menopause, age at study entry, and time interval between blood draws. Ovarian volume was calculated using measurements obtained from transvaginal ultrasound in both cases and controls and measurements recorded in surgical pathology reports from cases. Serum hormone levels of testosterone, androstenedione, androstenediol, dihydrotestosterone, androsterone, dehydroepiandrosterone, estrone, estradiol, and sex hormone–binding globulin were measured at baseline and follow-up. Spearman correlation coefficients were used to compare ovarian volumes as measured on transvaginal ultrasound and pathology examinations. Correlations between ovarian volumes by transvaginal ultrasound and measured hormone levels were examined using linear regression models. All models were adjusted for age. Paired t tests were performed to evaluate individual differences in hormone levels before and after risk-reducing salpingo-oophorectomy.

      Results

      Ovarian volumes measured by transvaginal ultrasound were only moderately correlated with those reported on pathology reports (Spearman rho [ρ]=0.42). The median time interval between risk-reducing salpingo-oophorectomy and follow-up for the cases was 13.3 months (range, 6.0–19.3), and the median time interval between baseline and follow-up for the controls was 12.7 months (range, 8.7–13.4). Sex steroid levels decreased with age but were not correlated with transvaginal ultrasound ovarian volume, body mass index, or time since menopause. Estradiol levels were significantly lower after risk-reducing salpingo-oophorectomy (percentage change, −61.9 post-risk-reducing salpingo-oophorectomy vs +15.2 in controls; P=.02), but no significant differences were seen for the other hormones.

      Conclusion

      Ovarian volumes measured by transvaginal ultrasound were moderately correlated with volumes directly measured on pathology specimens and were not correlated with sex steroid hormone levels in postmenopausal women. Estradiol was the only hormone that declined significantly after risk-reducing salpingo-oophorectomy. Thus, it remains unclear whether the limited post–risk-reducing salpingo-oophorectomy changes in sex steroid hormones among postmenopausal women impact long-term adverse outcomes.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Obstetrics & Gynecology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Antoniou A.
        • Pharoah P.D.
        • Narod S.
        • et al.
        Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies.
        Am J Hum Genet. 2003; 72: 1117-1130
        • Kuchenbaecker K.B.
        • Hopper J.L.
        • Barnes D.R.
        • et al.
        Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers.
        JAMA. 2017; 317: 2402-2416
        • Jasperson K.W.
        • Tuohy T.M.
        • Neklason D.W.
        • Burt R.W.
        Hereditary and familial colon cancer.
        Gastroenterology. 2010; 138: 2044-2058
        • Moller P.
        • Seppala T.T.
        • Bernstein I.
        • et al.
        Cancer risk and survival in path_MMR carriers by gene and gender up to 75 years of age: a report from the Prospective Lynch Syndrome Database.
        Gut. 2018; 67: 1306-1316
        • Toss A.
        • Tomasello C.
        • Razzaboni E.
        • et al.
        Hereditary ovarian cancer: not only BRCA 1 and 2 genes.
        BioMed Res Int. 2015; 2015: 341723
        • Eoh K.J.
        • Kim J.E.
        • Park H.S.
        • et al.
        Detection of germline mutations in patients with epithelial ovarian cancer using multi-gene panels: beyond BRCA1/2.
        Cancer Res Treat. 2018; 50: 917-925
        • Harter P.
        • Hauke J.
        • Heitz F.
        • et al.
        Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1).
        PLoS One. 2017; 12e0186043
        • Walsh T.
        • Casadei S.
        • Lee M.K.
        • et al.
        Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
        Proc Natl Acad Sci U S A. 2011; 108: 18032-18037
        • Domchek S.M.
        • Friebel T.M.
        • Singer C.F.
        • et al.
        Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
        JAMA. 2010; 304: 967-975
        • Rebbeck T.R.
        • Kauff N.D.
        • Domchek S.M.
        Meta-analysis of risk reduction estimates associated with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers.
        J Natl Cancer Inst. 2009; 101: 80-87
        • Finch A.P.
        • Lubinski J.
        • Moller P.
        • et al.
        Impact of oophorectomy on cancer incidence and mortality in women with a BRCA1 or BRCA2 mutation.
        J Clin Oncol. 2014; 32: 1547-1553
        • Kauff N.D.
        • Satagopan J.M.
        • Robson M.E.
        • et al.
        Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation.
        N Engl J Med. 2002; 346: 1609-1615
        • Mavaddat N.
        • Peock S.
        • Frost D.
        • et al.
        Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE.
        J Natl Cancer Inst. 2013; 105: 812-822
        • Schiffer L.
        • Arlt W.
        • Storbeck K.H.
        Intracrine androgen biosynthesis, metabolism and action revisited.
        Mol Cell Endocrinol. 2018; 465: 4-26
        • Key T.J.
        • Appleby P.N.
        • et al.
        • Endogenous Hormones and Breast Cancer Collaborative Group
        Circulating sex hormones and breast cancer risk factors in postmenopausal women: reanalysis of 13 studies.
        Br J Cancer. 2011; 105: 709-722
        • Laughlin G.A.
        • Barrett-Connor E.
        • Kritz-Silverstein D.
        • von Muhlen D.
        Hysterectomy, oophorectomy, and endogenous sex hormone levels in older women: the Rancho Bernardo Study.
        J Clin Endocrinol Metab. 2000; 85: 645-651
        • Chubak J.
        • Tworoger S.S.
        • Yasui Y.
        • Ulrich C.M.
        • Stanczyk F.Z.
        • McTiernan A.
        Associations between reproductive and menstrual factors and postmenopausal androgen concentrations.
        J Womens Health (Larchmt). 2005; 14: 704-712
        • Stanczyk F.Z.
        • Chaikittisilpa S.
        • Sriprasert I.
        • Rafatnia A.
        • Nadadur M.
        • Mishell D.R.
        Circulating androgen levels before and after oophorectomy in premenopausal and postmenopausal women.
        Climacteric. 2019; 22: 169-174
        • Fogle R.H.
        • Stanczyk F.Z.
        • Zhang X.
        • Paulson R.J.
        Ovarian androgen production in postmenopausal women.
        J Clin Endocrinol Metab. 2007; 92: 3040-3043
        • Davison S.L.
        • Bell R.
        • Donath S.
        • Montalto J.G.
        • Davis S.R.
        Androgen levels in adult females: changes with age, menopause, and oophorectomy.
        J Clin Endocrinol Metab. 2005; 90: 3847-3853
        • Couzinet B.
        • Meduri G.
        • Lecce M.G.
        • et al.
        The postmenopausal ovary is not a major androgen-producing gland.
        J Clin Endocrinol Metab. 2001; 86: 5060-5066
        • Parker W.H.
        • Broder M.S.
        • Liu Z.
        • Shoupe D.
        • Farquhar C.
        • Berek J.S.
        Ovarian conservation at the time of hysterectomy for benign disease.
        Obstet Gynecol. 2005; 106: 219-226
        • Parker W.H.
        • Feskanich D.
        • Broder M.S.
        • et al.
        Long-term mortality associated with oophorectomy compared with ovarian conservation in the Nurses’ Health Study.
        Obstet Gynecol. 2013; 121: 709-716
        • Hickey M.
        • Ambekar M.
        • Hammond I.
        Should the ovaries be removed or retained at the time of hysterectomy for benign disease?.
        Hum Reprod Update. 2010; 16: 131-141
        • Michelsen T.M.
        • Pripp A.H.
        • Tonstad S.
        • Trope C.G.
        • Dorum A.
        Metabolic syndrome after risk-reducing salpingo-oophorectomy in women at high risk for hereditary breast ovarian cancer: a controlled observational study.
        Eur J Cancer. 2009; 45: 82-89
        • Kurita K.
        • Henderson V.W.
        • Gatz M.
        • et al.
        Association of bilateral oophorectomy with cognitive function in healthy, postmenopausal women.
        Fertil Steril. 2016; 106: 749-756.e2
        • Gierach G.L.
        • Pfeiffer R.M.
        • Patel D.A.
        • et al.
        Long-term overall and disease-specific mortality associated with benign gynecologic surgery performed at different ages.
        Menopause. 2014; 21: 592-601
        • Sherman M.E.
        • Lacey J.V.
        • Buys S.S.
        • et al.
        Ovarian volume: determinants and associations with cancer among postmenopausal women.
        Cancer Epidemiol Biomarkers Prev. 2006; 15: 1550-1554
        • Elfayomy A.K.
        • El Tarhouny S.A.
        Ovarian volume assessment in relation to histologic findings and sex hormone levels in women with postmenopausal bleeding and thickened endometrium.
        Ann Saudi Med. 2012; 32: 588-592
        • Sherman M.E.
        • Madigan M.P.
        • Lacey Jr., J.V.
        • et al.
        Ovarian volumes among women with endometrial carcinoma: associations with risk factors and serum hormones.
        Gynecol Oncol. 2007; 107: 431-435
        • Armeni E.
        • Tsitoura A.
        • Aravantinos L.
        • et al.
        Ovarian volume is associated with adiposity measures and bone mineral density in postmenopausal women.
        J Musculoskelet Neuronal Interact. 2018; 18: 501-508
        • Greene M.H.
        • Piedmonte M.
        • Alberts D.
        • et al.
        A prospective study of risk-reducing salpingo-oophorectomy and longitudinal CA-125 screening among women at increased genetic risk of ovarian cancer: design and baseline characteristics: a Gynecologic Oncology Group Study.
        Cancer Epidemiol Biomarkers Prev. 2008; 17: 594-604
        • Sherman M.E.
        • Piedmonte M.
        • Mai P.L.
        • et al.
        Pathologic findings at risk-reducing salpingo-oophorectomy: primary results from Gynecologic Oncology Group Trial GOG-0199.
        J Clin Oncol. 2014; 32: 3275-3283
        • Skates S.J.
        Ovarian cancer screening: development of the risk of ovarian cancer algorithm (ROCA) and ROCA screening trials.
        Int J Gynecol Cancer. 2012; 22: S24-S26
        • Skates S.J.
        • Greene M.H.
        • Buys S.S.
        • et al.
        Early detection of ovarian cancer using the risk of ovarian cancer algorithm with frequent CA125 testing in women at increased familial risk - combined results from two screening trials.
        Clin Cancer Res. 2017; 23: 3628-3637
        • van Nagell Jr., J.R.
        • Miller R.W.
        • DeSimone C.P.
        • et al.
        Long-term survival of women with epithelial ovarian cancer detected by ultrasonographic screening.
        Obstet Gynecol. 2011; 118: 1212-1221
        • Sharma A.
        • Burnell M.
        • Gentry-Maharaj A.
        • et al.
        Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
        Ultrasound Obstet Gynecol. 2016; 47: 228-235
        • Sharma A.
        • Burnell M.
        • Gentry-Maharaj A.
        • et al.
        Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS).
        Ultrasound Obstet Gynecol. 2013; 42: 472-477
        • Bodelon C.
        • Pfeiffer R.M.
        • Buys S.S.
        • Black A.
        • Sherman M.E.
        Analysis of serial ovarian volume measurements and incidence of ovarian cancer: implications for pathogenesis.
        J Natl Cancer Inst. 2014; 106: dju262
        • Stott W.
        • Campbell S.
        • Franchini A.
        • et al.
        Sonographers’ self-reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images from UKCTOCS.
        Ultrasound Obstet Gynecol. 2018; 51: 401-408
        • Duan L.
        • Xu X.
        • Koebnick C.
        • et al.
        Bilateral oophorectomy is not associated with increased mortality: the California Teachers Study.
        Fertil Steril. 2012; 97: 111-117

      Supplemental References

        • Audet-Walsh E.
        • Lepine J.
        • Gregoire J.
        • et al.
        Profiling of endogenous estrogens, their precursors, and metabolites in endometrial cancer patients: association with risk and relationship to clinical characteristics.
        J Clin Endocrinol Metab. 2011; 96: E330-E339
        • Labrie F.
        • Belanger A.
        • Belanger P.
        • et al.
        Androgen glucuronides, instead of testosterone, as the new markers of androgenic activity in women.
        J Steroid Biochem Mol Biol. 2006; 99: 182-188